UNQUOTE

UK - AGF et al. invest $4.5m in Vivacta

  • frannie
  • LinkedIn  
  • Google plus  

Existing investors AGF Private Equity, HBM Bioventures, Spark Ventures and Viking Technologies have invested $4.5m into Vivacta, a UK-based blood-drop test developer.

Based in Kent, Vivacta has developed a blood-drop test for thyroid functionality. The clinical evaluation of the system has now commenced and the company anticipates achieving regulatory clearance within 12 months. The cartridge pilot manufacturing facility has commenced weekly manufacturing campaigns for internal evaluation. Validation of the facility and product is planned for later this year
  • LinkedIn  
  • Google plus  

More on Early-stage

Latest News